

# Circulating Biomarker Testing For Abdominal Aortic Aneurysm Incidence and Identification

Agastya Vaidya, BS<sup>1</sup>, Neil Patel, BS, MBA<sup>1</sup>, Rahman Sayed, BS<sup>1</sup>, Jeffrey Indes, MD<sup>2</sup>

<sup>1</sup>Albert Einstein College of Medicine, Bronx, NY, USA, <sup>2</sup>UMass Chan Medical School-Lahey, Burlington, MA, USA

## BACKGROUND

- Abdominal aortic aneurysm (AAA) continues to be a leading cause of death in the United States, necessitating adequate screening to reduce mortality.
- The United States Preventive Services Task Force (USPSTF) recommends 1-time screening for AAA with ultrasound in men aged 65 to 75 who have ever smoked.
- Despite efforts by the USPSTF to improve AAA screening at-risk populations, underutilization continues to be reported with access and racial disparity being associated. [1]
- Prior research has shown the role of circulating biomarkers in the development of major cardiovascular disorders and has been theorized that these markers can predict the risk of CVD. [2]

## OBJECTIVE

- To investigate biomarker association with AAA incidence and subsequent rupture

## METHODS

- Study Design:** Retrospective cohort study using a multi-institutional database.
- Population:** Hospital patients who underwent biomarker blood testing 1-year prior to identification of a new intact AAA
  - Secondary outcome with patients with intact AAA matched to patients with ruptured AAA
  - Matching criteria included: Age, essential hypertension, diabetes, chronic kidney disease (CKD), and chronic obstructive pulmonary disease (COPD)
- Biomarkers Assessed** (by quartile):
  - White Blood Cell Count** (per  $\mu$ L)
  - D-Dimer** (in mg/L FEU)
  - Cardiac Troponin** (or cTnT) (in pg/mL)
  - N-Terminal pro-B-type natriuretic peptide** (or NT-proBNP) (in pg/mL)
  - C-reactive protein** (in mg/L)
- Outcomes Assessed:**
  - Odds ratio:** comparison of incidence of intact AAA versus no AAA by quartile within 1 year of initial biomarker values
  - Comparison** of incidence of intact versus ruptured AAA within 1 year of initial biomarker values

- Statistical Analysis:**
  - Independent t-tests** evaluated differences **between open and endovascular groups**.

## RESULTS

Quartile	Biomarker	With Intact AAA	Without AAA	Odds Ratio	95% Confidence Interval
	WBC	n = 81330	n = 21148838		
1	< 4.89	10777	3257546	0.839	(0.822, 0.856)
2	4.9 - 5.89	14202	4175251	0.860	(0.845, 0.876)
3	5.9 - 7.09	21088	5432408	1.013	(0.997, 1.029)
4	7.1 >	35263	8283633	1.189	(1.172, 1.205)
	D-Dimer	n = 1653	n = 654298		
1	< 0.1699	19	27837	0.262	(0.116, 0.411)
2	0.17 - 0.2699	16	50274	0.117	(0.072, 0.192)
3	0.27 - 0.4399	82	126537	0.218	(0.174, 0.272)
4	> 0.44	1536	449650	5.975	(4.951, 7.211)
	cTnT	n = 5861	n = 1056896		
1	< 2.99	1165	288912	0.659	(0.618, 0.703)
2	3 - 4.99	34	14924	0.407	(0.219, 0.571)
3	5 - 8.99	163	44002	0.659	(0.563, 0.770)
4	> 9	4499	709058	1.620	(1.525, 1.722)
	NT-proBNP	n = 7254	n = 1227734		
1	< 33.09	661	279407	0.340	(0.314, 0.369)
2	33.1 - 67.19	901	225246	0.631	(0.589, 0.677)
3	67.2 - 129.19	1293	231516	0.933	(0.879, 0.991)
4	> 129.2	4399	491565	2.308	(2.201, 2.419)
	CRP	n = 6666	n = 2781232		
1	< 1.089	999	557372	0.703	(0.658, 0.752)
2	1.09 - 2.439	660	388152	0.678	(0.625, 0.734)
3	2.44 - 5.449	1108	554029	0.801	(0.751, 0.855)
4	> 5.45	3899	1281679	1.649	(1.570, 1.731)

Table 1: Odds ratio of intact AAA diagnosis 1-year after biomarker collection in comparison to no AAA diagnosis

- Associations with AAA incidence were observed with WBC count, D-Dimer, cTnT, NT-proBNP, and CRP
- In all biomarker categories, there was a statistically significant odds ratio between prevalence of AAA in the 4<sup>th</sup> quartile of each respective lab result.
- 1<sup>st</sup> and 2<sup>nd</sup> quartile WBC counts had lower incidence in comparison to 4<sup>th</sup> quartile
- The bottom 3 quartiles in the D-Dimer, cTnT, and CRP had significantly lower odds ratios in comparison than the 4<sup>th</sup> quartile

## CONCLUSIONS

- There were significant associations with AAA incidence 1-year after collection of biomarker labs (i.e. WBC count, D-Dimer, cTnT, NT-proBNP, and CRP).
- The matched analysis revealed that patients with lower WBC counts (<11 WBC/  $\mu$ L) and BNP (<129.2 pg/mL) had significantly lower AAA rupture incidence (p=0.002 and p<0.0001, respectively) and significantly lower intact AAA incidence (p=0.03 and p<0.0001, respectively).
- Lower D-Dimer (<0.44 mg/L FEU), cTnT (<0.04 ng/mL), and CRP (<5.45 mg/L) levels correlated to significantly lower intact AAA incidence (p<0.0001, p=0.0026, and p=0.0002, respectively) during matched analysis.
- These findings further underline the possible clinical relevance of WBC count, D-Dimer, cTnT, and CRP as AAA risk indicators at least 1-year prior to identification.
- Meanwhile, WBC and NT-proBNP levels could be possible factors related to risk of rupture assessments.
- Further investigation using machine learning and other AI applications may yield further methodology in this investigation into using biomarkers as an alternative to AAA screening in hopes to increase accessibility.

## REFERENCES

- [1] Anjorin, Aderike, et al. "Underutilization of Guideline-based Abdominal Aortic Aneuysm Screening in an Academic Health System" *Annals of Vascular Surgery*, vol. 83, 2022, pp. 184–194.
- [2] Gupta, Lovish, et al. "Inflammation in Cardiovascular Disease: A Comprehensive Review of Biomarkers and Therapeutic Targets" *Cureus*, vol. 15, no. 9, 2023.



Society for Clinical  
Vascular Surgery